Table 5.
Group | No. of studies | Point estimate | 95% CI | I2 | Q | p | |
---|---|---|---|---|---|---|---|
Lower | Upper | ||||||
Screening timepoint | |||||||
Postpartum | 7 | −0.36 | −0.48 | − 0.24 | 40.71% | 0.93 | 0.34 |
Antenatal | 3 | −0.23 | − 0.47 | 0.002 | 38.29% | ||
Tool | |||||||
EPDS | 7 | −0.31 | −0.43 | − 0.19 | 33.09% | 4.14 | 0.25 |
EPDS & clinical | 1 | −0.52 | −0.81 | − 0.24 | 0 | ||
EPDS & PHQ-9 | 1 | −0.23 | −0.49 | 0.03 | 0 | ||
Risk index | 1 | −0.94 | −1.85 | − 0.03 | 0 | ||
Mode of screening | |||||||
In-person interviews | 5 | −0.39 | − 0.57 | −0.20 | 10.55% | 0.95 | 0.81 |
Postal | 1 | −0.23 | −0.58 | 0.11 | 0% | ||
Multiple methods | 2 | −0.27 | − 0.55 | 0.01 | 0% | ||
Self-administereda | 2 | −0.38 | −0.69 | − 0.08 | 88.23% |
aIncludes online delivery